Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Solid Tumor, Adult · Solid Tumor · CTMX

CytomX Therapeutics

CytomX Therapeutics patent portfolio — 62 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
South San Francisco, USA HQ
98 Employees
Public company Type
CTMX · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Employees
98
Programs
8
Drugs
0
Patents
62
Official website ↗ All projects Patents News & analysis
Intelligence · Patents

CytomX Therapeutics patents

62 pharmaceutical patents indexed for CytomX Therapeutics. 0 expire within 24 months.

CytomX Therapeutics has 62 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

62 patents

Patent portfolio

Page 1 of 2

  1. US 12428470

    Compositions containing activatable antibodies

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12139543

    Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12049505

    Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11992528

    Compositions and methods for conjugating activatable antibodies

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11952427

    Anti-CD40 antibodies and uses thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11890354

    Activatable antibodies that bind epidermal growth factor receptor and methods thereof

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11884746

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11867695

    Compositions and methods for detecting protease activity in biological systems

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11859010

    Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11814410

    Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11802158

    Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11753466

    Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11667687

    Masked activatable interferon constructs

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11548943

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11548944

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11472889

    Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11472875

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11306149

    Anti-CD40 antibodies and uses thereof

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11267896

    Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11180562

    Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11174316

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11168144

    Activatable anti-PDL1 antibodies, and methods of use thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11161906

    Multispecific antibodies, multispecific activatable antibodies and methods of using the same

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11117968

    Activatable anti-CTLA-4 antibodies and uses thereof

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11046759

    Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

    Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11035859

    Compositions and methods for detecting protease activity in biological systems

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11028126

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10875913

    Methods of treatment using activatable anti-EGFR antibodies

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10800850

    Therapeutic antibodies

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10745481

    Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10709799

    Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10669337

    Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10669339

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10611845

    Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10568977

    Antibodies that bind activatable antibodies and methods of use thereof

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10533053

    Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10513549

    Cleavage-activatable interferon-alpha proprotein

    Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10513558

    Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

    Expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10336824

    Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10301380

    Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10261083

    Compositions and methods for detecting protease activity in biological systems

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10233244

    Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10179817

    Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

    Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10138272

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10118961

    Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10059762

    Anti-EGFR activatable antibodies

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9889211

    Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9737623

    Antibodies that bind activatable antibodies and methods of use thereof

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does CytomX Therapeutics have?

62 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do CytomX Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.